Trial · NCT07885267
Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors
NCT07885267, Phase 1, Completed, Antido Therapeutics (Australia) Pty Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors. Trials, record NCT07885267. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885267
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors
- NCT number
- NCT07885267
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 26 participants, actual
- Lead sponsor
- Antido Therapeutics (Australia) Pty Ltd
- Conditions
- Advanced Solid Tumor
- Interventions
- AT-0174
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with dose-limiting toxicities (DLTs) | Cycle 1 (28 days) | DLTs graded per NCI CTCAE v5.0. |
| Primary | Number of participants with treatment-emergent adverse events | From first dose through 30 days after last dose | Adverse events graded per NCI CTCAE v5.0. |
| Primary | Recommended Phase 2 dose (RP2D) of AT-0174 | Through study completion, approximately 33 months | Determined from safety and tolerability data. |
| Secondary | Percent change from baseline in plasma kynurenine (KYN) and tryptophan (TRP) concentrations | Baseline (pre-dose) through Cycle 4 (28-day cycles) | Plasma KYN and TRP measured before and after AT-0174 dosing, as a pharmacodynamic measure of TDO2/IDO1 pathway inhibition. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885267
GET https://conductscience.org/api/trials/v1/NCT07885267/registered